a-001
Acute Chest Syndrome
Anthera PharmaceuticalsPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
2 Active assets in the Acute Chest Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tocilizumab Assistance Publique - Hôpitaux de Paris | Phase 3 | BB |
Tinzaparin Assistance Publique - Hôpitaux de Paris | Phase 3 | B |
Lipitor Dr. med. Mahir Karakas | Phase 3 | B |
Acetylsalicylic Acid Dr. med. Mahir Karakas | Phase 3 | B |
Defibrotide New York Medical College | Phase 2 | B |
View all 10 →
Same molecule, other indications
a-001 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →